26-Dec-2025
Business Wire (Mon, 17-Nov 4:01 PM ET)
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
Business Wire (Tue, 4-Nov 7:00 AM ET)
Business Wire (Mon, 20-Oct 7:00 AM ET)
Business Wire (Tue, 7-Oct 7:00 AM ET)
Business Wire (Thu, 2-Oct 4:01 PM ET)
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Business Wire (Tue, 30-Sep 9:00 PM ET)
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
Business Wire (Tue, 30-Sep 4:11 PM ET)
Enanta to Reveal Phase 2b RSV Study Results for Zelicapavir—Investors Await Monday’s Conference Call
Market Chameleon (Mon, 29-Sep 6:35 AM ET)
Market Chameleon (Mon, 29-Sep 3:06 AM ET)
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
Enanta Pharmaceuticals trades on the NASDAQ stock market under the symbol ENTA.
As of December 26, 2025, ENTA stock price climbed to $16.85 with 214,913 million shares trading.
ENTA has a beta of 1.69, meaning it tends to be more sensitive to market movements. ENTA has a correlation of 0.16 to the broad based SPY ETF.
ENTA has a market cap of $486.17 million. This is considered a Small Cap stock.
Last quarter Enanta Pharmaceuticals reported $15 million in Revenue and -$.87 earnings per share. This fell short of revenue expectation by $-697,360 and exceeded earnings estimates by $.19.
In the last 3 years, ENTA traded as high as $62.06 and as low as $4.09.
The top ETF exchange traded funds that ENTA belongs to (by Net Assets): VTI, IWM, IWN, IBB, VXF.
ENTA has outperformed the market in the last year with a price return of +176.2% while the SPY ETF gained +16.0%. ENTA has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +115.7% and +17.3%, respectively, while the SPY returned +4.7% and +0.7%, respectively.
ENTA support price is $15.99 and resistance is $17.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENTA shares will trade within this expected range on the day.
